199 results about "Squamous Carcinomas" patented technology

The invention relates to a composition for identifying oral squamous cell carcinoma based on saliva sample detection and application, and belongs to the technical field of molecular biology. The composition provided by the invention is used for identifying the oral squamous cell carcinoma by detecting the expression of SNORD52 and / or SNORD65 in a saliva sample; the composition comprises a specific reverse transcription stem-loop primer, a specific detection forward primer, a specific detection probe and a universal reverse primer. According to the composition disclosed by the invention, the expression of SNORD52 and / or SNORD65 in a saliva sample is detected, and a binomial logistic regression model is combined to perform auxiliary judgment on the oral squamous cell carcinoma, so that the composition has relatively high sensitivity and specificity, and the identification accuracy of the oral squamous cell carcinoma can be improved. The invention further provides a kit containing the composition, a detection object of the kit is a saliva sample, and the kit has the advantages of being small in sample dosage, noninvasive in sampling, convenient, rapid, small in risk and the like.

The invention discloses an engineered bionic nucleic acid nano-vesicle as well as a preparation method and application thereof, relates to the technical field of nano biomedicine, and aims at solving the problems that in-vivo targeting efficiency and immunogenicity of a traditional cationic lipid nano-carrier are limited due to deletion and cleavage obstacles of GSDMD expression in tumor cells. The technical key point of the invention is as follows: the engineered bionic nucleic acid nano-vesicle is provided and is prepared by wrapping a cationic lipid nucleic acid drug with an exosome derived from engineered macrophages; wherein the exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1, which is as shown in SEQ. ID. NO.1. The exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1; the lipid nucleic acid medicine is prepared by loading GSDMD-N mRNA (messenger Ribonucleic Acid) shown on the basis of SEQ.ID.NO.2 on a cationic liposome. The engineered bionic nucleic acid nano-vesicle is used for preparing an oral squamous cell carcinoma diagnostic kit and a therapeutic drug.

The invention provides a micro-fluidic chip capable of culturing oral squamous cell carcinoma organoid and a preparation method thereof, and relates to the technical field of micro-fluidic chips, the chip comprises a four-layer structure: the first layer is a closed layer, the second layer is a culture solution / drug pool layer (containing a concentration gradient injection channel and a slow flow channel), the third layer is a matrix culture pool layer, and the fourth layer is a matrix culture pool layer. The fourth layer is a matrigel inflow layer (containing an S-shaped flow channel); the second layer and the third layer are integrally formed, and all the layers are connected through oxygen plasma welding; the problems that in the prior art, matrigel is prone to shifting, drug gradient regulation and control is poor, operation is tedious, and adaptability is insufficient are solved, the matrigel and organoids can be stably fixed, the drug concentration gradient can be precisely regulated and controlled, the nutrition supply efficiency is enhanced, the structural integration level and operation convenience are improved, and the application prospect is wide. The method is suitable for oral squamous cell carcinoma organoid culture, drug screening and tumor mechanism research.

The invention provides equipment, a method and a system for evaluating prognosis of cervical cancer, squamous carcinoma and adenocarcinoma and application of the equipment, the method and the system, and belongs to the technical field of medical evaluation. Two biomarkers, namely adenylate kinase 4 and cavernous malformation 2 protein, for evaluating prognosis of cervical squamous cell carcinoma and adenocarcinoma are obtained through multivariate statistical analysis, difference screening, COX regression analysis and other biosignal analysis methods. Based on the biomarker, evaluation equipment, a computer execution method, a computer system and the like for evaluating the prognosis of cervical squamous cell carcinoma and adenocarcinoma are constructed, and the evaluation equipment, the computer execution method, the computer system and the like are used for accurately judging the prognosis condition of a cervical cancer patient.

The invention discloses a computer-aided drug screening method, system or device based on FBXO2 and PKM2. The invention provides a brand-new method, system or equipment for screening oral squamous cell carcinoma treatment drugs based on FBXO2 and PKM2, provides a tool for new drug development and clinical application for treatment of oral squamous cell carcinoma, and has a wide application prospect.

The invention discloses an engineered bionic nucleic acid nano diagnosis and treatment agent as well as a preparation method and application thereof, relates to the technical field of biological targeting, and aims to solve the problems that an engineered macrophage membrane modified bionic nucleic acid nano diagnosis and treatment agent for oral squamous cell carcinoma is lacked in the prior art, and the curative effect on invasive tumors of the oral squamous cell carcinoma is poor. According to the engineering bionic nucleic acid nano diagnosis and treatment agent, a cationic lipid nucleic acid medicine is wrapped with a macrophage membrane, and PD1 shown as SEQ.ID.NO.1 is stably expressed on the macrophage membrane; the cationic lipid nucleic acid medicine is prepared by loading Cip2a siRNA (small interfering Ribonucleic Acid) on a cationic liposome. The bionic nucleic acid nano diagnosis and treatment agent has a huge application prospect in preparation of oral squamous cell carcinoma diagnosis kits and medicines.

The present invention relates to immunoconjugates specific for human EPH receptor A5 (EphA5), methods of treatment of cancers (e.g., carcinomas including squamous cell carcinoma, and colorectal cancer) using said immunoconjugates, and related pharmaceutical compositions of said immunoconjugates.

This invention relates to human papilloma virus (HPV) positive cancers such as HPV+ squamous cell carcinoma of the oropharynx (OPSCC). This invention further relates methods of determining treatment regimens, methods of stratifying prognosis from treatment of HPV positive cancers, methods of determining suitability for de-escalation of treatment of HPV positive cancers, and methods of treating HPV positive cancers.

The invention discloses a receptor helper protein 6 and application of an inhibitor thereof in preparation of a medicine for treating oral squamous cell carcinoma. The invention discloses a receptor helper protein 6 as a novel ferroptosis inhibiting factor in OSCC cells, which is a key protein in a ferroptosis signal pathway and can be used as a drug target for overcoming the progress of oral squamous cell carcinoma. The knock-down of the REEP6 significantly inhibits the cell reproduction rate in the OSCC cell line, significantly promotes DNA damage in the OSCC cell line and significantly inhibits migration and invasion of the OSCC cell line, so that the inhibitor of the targeted receptor helper protein 6 can be applied as a drug for treating oral squamous cell carcinoma. The invention provides a new thought for diagnosing and preparing medicines for treating oral squamous cell carcinoma.

The invention belongs to the technical field of biological medicine, and provides self-assembled polypeptide targeting mitochondria, a preparation method and application of the self-assembled polypeptide, a self-assembled polypeptide microneedle patch and a preparation method of the self-assembled polypeptide microneedle patch. According to the self-assembly polypeptide of the targeted mitochondria, the amino acid sequence is GFFGKXRXKXRX, and X represents cyclohexyl alanine. A targeting peptide (Mito) sequence KXRXKXRX can recognize cell mitochondria in a targeting manner, a self-assembly sequence GFFG is introduced to an N terminal of the Mito sequence KXRXKXRX, and the targeting peptide sequence is endowed with a self-assembly capability, so that the self-assembly polypeptide can cause morphological function abnormality of mitochondria in tumor cells, the tumor cells are killed, and inhibition of the tumor cells is realized. The self-assembled polypeptide disclosed by the invention is applied to treatment of tumor cells through in-situ administration of the self-assembled polypeptide microneedle patch. Oral squamous cell carcinoma serves as a highly proliferated tumor cell, rapid proliferation of the oral squamous cell carcinoma needs a large amount of energy supply for mitochondria, and therefore attacking of the mitochondria can serve as an effective treatment target.

The invention discloses application of a reagent for detecting FOXA2 in preparation of a kit for diagnosis or differentiation degree evaluation and prognosis evaluation of head and neck squamous cell carcinoma. Wherein the reagent comprises a primer pair for amplifying the FOXA2; the primer pair comprises an upstream primer with a nucleotide sequence as shown in SEQ ID NO. 1 and a downstream primer with a nucleotide sequence as shown in SEQ ID NO. 2. By utilizing the kit, diagnosis, differentiation degree evaluation and prognosis evaluation of head and neck squamous cell carcinoma and oral squamous cell carcinoma can be effectively realized, and the kit is high in accuracy and good in repeatability.

The invention discloses antisense oligonucleotide for adjuvant therapy of oral squamous cell carcinoma and application of the antisense oligonucleotide. According to the invention, the rs737540 site and the mutant allele rs737540-T thereof are identified, so that the problem of lack of specific biomarkers and targeted therapy means in the prior art is solved. By designing the antisense oligonucleotide aiming at the rs737540 mutation site, selective splicing of TARDBP and EGFR exon 4 can be specifically blocked, and OSCC cell proliferation is inhibited. Besides, the EGFR targeted drug cetuximab is used in a combined manner, so that a stronger anti-cancer effect is realized, and the blank in the existing treatment means is filled. The core breakthrough of the technology is that genetic variation and targeted therapy are combined, and a new research thought and a clinical application prospect are provided for precise medicine of oral squamous cell carcinoma.

A method of collecting oral mucosal cells from a patient and evaluating the oral mucosal cells for oral squamous cell carcinoma predisposition in the patient includes collecting a sample of chewing gum from a patient that had chewed the chewing gum for a minimum of about 5 minutes up to about 30 minutes. The chewing gum includes a molecular adherent targeted towards oral mucosal cells with oral squamous cell carcinoma predisposition. A polymerase chain reaction (PCR) is performed on a DNA template prepared from the chewed chewing gum using oligonucleotide primers that are selected to amplify nucleic acids that screen for genomic sequence variations seen in genes that are indicative of oral squamous cell carcinoma predisposition in the patient.

The present invention relates to a method of predicting the vulnerability of a squamous cell carcinoma (SCC) to inhibition by a PI3K inhibitor, preferably by a PI3K / mTOR inhibitor, including the selection of the patient predicted to benefit from therapeutic administration with the PI3K inhibitor, preferably of the PI3K / mTOR inhibitor. Moreover, the present invention relates to a method of treating a squamous cell carcinoma (SCC) of a mammal, preferably a human patient, comprising administering a therapeutically effective amount of a PI3K inhibitor, preferably a therapeutically effective amount of a PI3K / mTOR inhibitor to said mammal, preferably said human patient. Furthermore, the present invention relates to pharmaceutical compositions and kits associated with the inventive methods.

The invention relates to the field of biomedicine, and discloses an expiration marker combination for diagnosing oral squamous cell carcinoma as well as application and a screening method of the expiration marker combination. Wherein the expiration marker combination comprises 29 oral expiration markers, a scoring model is constructed through the relative content of VOC signals of the expiration markers, the scoring model can be used for evaluating the oral squamous cell carcinoma risk of a patient, and the invention further discloses a screening method of the expiration marker combination. According to the screening method, a multi-algorithm feature union set strategy is adopted, the algorithm advantages of UTest, Boruta, LGBM, RF and the like are integrated, the limitation of a single algorithm is overcome, and the OSCC related expiration markers are recognized to the maximum extent. The core marker screening basis is clear, the PTR-TOF-MS detection process is standard, an interpretable verification mechanism is constructed, clinical popularization is facilitated, invasive biopsy dependence is reduced, diagnosis efficiency and patient compliance are improved, and important clinical and social values are achieved.

The invention relates to the technical field of tumor molecular biology. The invention provides application of CTLA-4, TIM-3 and LAG-3 as immune checkpoints in screening of drugs for treating oral squamous cell carcinoma. According to the invention, expression differences of CTLA-4, TIM-3 and LAG-3 in oral squamous cell carcinoma tissues and normal tissues and correlation between expression of CTLA-4, TIM-3 and LAG-3 and CD8 + T cell infiltration are compared and analyzed, CTLA-4, TIM-3 and LAG-3 are screened as suitable immune checkpoints, and by inhibiting expression levels of CTLA-4, TIM-3 and LAG-3, activation and proliferation of T cells can be improved, positive regulation immune response can be increased, and the immunologic function of the oral squamous cell carcinoma is enhanced. Therefore, the oral squamous cell carcinoma treatment effect is improved.

The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).

The invention relates to a detection marker and a detection device for identifying primary and intrawall metastasis of esophageal multifocal squamous carcinoma, and belongs to the technical field of cancer detection markers. According to the invention, a detection site set composed of 20 genes is constructed, and the gene diagnosis purpose of distinguishing primary and intrawall metastasis of esophageal multi-lesion squamous cell carcinoma is realized by analyzing the difference of mutation types on lesions.

The invention relates to the technical field of image processing, and discloses an oral squamous cell carcinoma invasion depth measurement method and system based on artificial intelligence. The method comprises the steps of performing standardization processing on oral tissue slices through a three-dimensional preprocessing algorithm to obtain a tumor mask image and a confidence map, then performing multipoint sampling deployment of a virtual measurement agent on the tumor surface, detecting feasibility of an invasion path by using a tissue resistance model, performing multi-branch feature extraction and deep regression calculation through an OSCC-DepthNet network, and finally obtaining the tumor mask image and the confidence map through the OSCC-DepthNet network. And obtaining an invasion path and a depth value of each agent, fusing multi-agent measurement results by adopting a confidence weighting algorithm, and outputting an oral squamous cell carcinoma invasion depth value and an uncertainty estimation value. The technical problems that an existing oral squamous cell carcinoma invasion depth measurement method is insufficient in three-dimensional space measurement capacity, too high in calculation complexity, poor in real-time performance and lack of an effective uncertainty quantification mechanism are solved.

The invention discloses application of LncRNA GSEC in preparation of a medicine for treating oral squamous cell carcinoma, and relates to the technical field of biological medicine. The nucleotide sequence of the LncRNA GSEC is shown as SEQ ID NO: 1, the medicine contains an active component capable of inhibiting expression or functions of the LncRNA GSEC, the active component is one or more of siRNA, shRNA or a small-molecule inhibitor, and the medicine is used for inhibiting proliferation, migration and / or invasion of OSCC cells and / or inducing cell apoptosis. The specific high expression of the LncRNA GSEC in oral squamous cell carcinoma tissues and cells is disclosed for the first time, and the expression level of the LncRNA GSEC is remarkably and positively correlated with adverse clinical parameters such as tumor T staging and lymph node metastasis, so that the LncRNA GSEC is proved to serve as a novel molecular target with clinical application potential.

The invention relates to application of lactobacillus muricatum in preparation of a medicine for treating oral cancer, the oral cancer is oral squamous cell carcinoma, a C57BL / 6 mouse tongue squamous cell carcinoma model induced by a 4-NQO water drinking method and a C3H / HeN subcutaneous tumor model inoculated by SCC7 tumor cells are constructed, and the lactobacillus muricatum has a remarkable inhibition effect on the oral cancer; experiments prove that the number / area / volume / weight of tumors is remarkably reduced by the lactobacillus muricatum, tumor marginal infiltration and abnormal karyokinesis are effectively inhibited, the expression quantity of tumor proliferation markers is remarkably reduced, and obvious pathological changes do not appear in main organs (heart, liver, spleen, lung and kidney) of mice. The method for minimally invasive injection of the lactobacillus muricatum into the oral squamous cell cancer tumor is safe, drug resistance is not easily induced, the treatment scheme is standardized, and the method has good clinical application potential.

This invention relates to the interdisciplinary field of cell biology, experimental oncology, and translational medicine, specifically to a cancer-associated fibroblast cell line, its construction method, and its applications. This invention fills the research gap in mouse-derived oral squamous cell carcinoma-associated fibroblast cell line models and provides a method for constructing such a cell line. Through the inverted adherent culture and enzymatic digestion methods of this invention, a mouse-derived oral squamous cell carcinoma-associated fibroblast cell line with a clear origin, high purity, and long-term phenotypic and functional stability can be obtained. This allows for the establishment of a cryopreservable and resuscitable mouse oral squamous cell carcinoma-associated fibroblast cell bank, providing technical support for research related to the tumor microenvironment and immunotherapy.

The application discloses a Campylobacter for treating oral squamous cell carcinoma and application thereof. It is found by the application that a Campylobacter showae strain has significant anti-tumor activity on a mouse model of oral squamous cell carcinoma, can significantly inhibit tumor growth, and promote the formation of tertiary lymphoid structures in oral squamous cell carcinoma. Therefore, the Campylobacter showae strain and a composition thereof can be used for preparing products for preventing, treating, adjuvant treating or prognosis nursing oral squamous cell carcinoma, and provide a new microbial intervention strategy for oral squamous cell carcinoma and related immunotherapy.

The present invention belongs to the field of biomedicine technology, and discloses the use of a quercetin derivative Q3MG in the preparation of anti-tumor invasion and metastasis drugs and drugs for targeted degradation of pro-IL-1β protein in cancer cells. The present invention first discovered that Q3MG can significantly inhibit tumor invasion and metastasis by targeted degradation of pro-IL-1β protein in cancer cells, and has a good therapeutic effect on anti-tumor invasion and metastasis, especially squamous cell carcinoma; it reveals the importance of quercetin derivatives in the preparation of drugs for the treatment of squamous cell carcinoma invasion and metastasis, and even the potential value of flavonoid compounds in various other tumors, which has far-reaching clinical significance and important prospects for promotion and application.

The application discloses a new use of a biomarker AF131217.1, and particularly discloses application of the biomarker AF131217.1 in diagnosis and treatment of oral squamous cell carcinoma. The application proves that the AF131217.1 can be used as a diagnostic marker and a therapeutic target of the oral squamous cell carcinoma. The oral squamous cell carcinoma can be diagnosed by detecting the expression level of the AF131217.1. The AF131217.1 is used as a drug target to assist clinical operation treatment by inhibiting the expression of the AF131217.1, so that the cure rate of patients is improved, and the life quality of the patients is improved.

The application provides an oxazinane compound, a preparation method, a pharmaceutical composition and application, and a general formula of the oxazinane compound or a pharmaceutically acceptable salt thereof is shown as formula (I). The oxazinane compound has obvious proliferation inhibition effect on cancer cells, especially human head and neck squamous cell carcinoma cell strains HSC4, HSC3, HSC2, CAL33, SCC4 and human glioma cell strain U251, can block the cell cycle, effectively inhibit the phosphorylation level of key proteins in the PI3K / AKT / mTOR pathway at the molecular level, has the potential to be prepared into a new antitumor drug, and has a good market prospect.

The present invention relates to a kit for detecting biomarkers and differentiating histological subtypes of non-small cell lung cancer. The detection biomarkers of the present invention include detecting the methylation degree of one or more of human chromosomes chr20:47444720-47444924, chr20:47444217-47444339 or chr20:47444014-47444136 and their combinations. Through high-throughput sequencing and locus-specific methylation fluorescence quantitative PCR methods, the present invention has discovered methylation gene sequences that can distinguish adenocarcinoma and squamous cell carcinoma in non-small cell lung cancer.

The invention discloses an anti-PIK3IP1 nano antibody and application thereof, and relates to the technical field of biological medicines. The anti-PIK3IP1 nano antibody screened from a bactrian camel VHH immune library can be specifically combined with a PIK3IP1 antigen, and it can be known through determination of the affinity of the antibody that the affinity of the obtained nano antibody ranges from 10 <-8 > M to 10 <-7 > M order of magnitude, and the affinity is high. The nano antibody or the antigen binding fragment can be specifically bound with PIK3IP1, can be prepared into medicines for preventing or treating various tumors such as lung cancer, liver cancer, colorectal cancer, breast cancer, glioma, stomach cancer, esophagus cancer, oral squamous cell carcinoma or head and neck cancer, and has a wide application prospect.

The present disclosure relates to a novel method of treating squamous cell carcinoma (SCC), and in particular head and neck squamous cell carcinoma (HSSCC) and cutaneous carcinoma (CC) using MUC1-C inhibitors. Also described herein is a novel method of suppressing the progression of premalignant lesions to a squamous cell carcinoma.

The present invention relates to an application of a reagent for detecting a biomarker in preparing a product for diagnosing oral squamous cell carcinoma, wherein the reagent for detecting a biomarker comprises a reagent for detecting one or more of miR-331-3p, miR-642a-5p and miR-1282, wherein the reagent for detecting hsa-miR-331-3p, hsa-miR-642a-5p and hsa-miR-1282 is a primer, the upstream primer for detecting hsa-miR-331-3p is shown in SEQ ID NO: 2, the upstream primer for detecting hsa-miR-642a-5p is shown in SEQ ID NO: 3, the upstream primer for detecting hsa-miR-1282 is shown in SEQ ID NO: 4, and the downstream universal primer for detecting hsa-miR-331-3p, hsa-miR-642a-5p and hsa-miR-1282 is shown in SEQ ID NO: 5. The present invention finds that hsa-miR-331-3p is significantly highly expressed in oral squamous cell carcinoma and can be used as a potential biomarker for oral squamous cell carcinoma; the present invention finds that after down-regulating the expression of hsa-miR-331-3p, it can significantly inhibit the proliferation and invasion of oral squamous cell carcinoma cells and can be used as a potential target for the treatment of oral squamous cell carcinoma.